{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Twist Bioscience Corp.
Twist Bioscience Stock Hits Day Low of $25.51 Amid Price Pressure
Twist Bioscience Corp. has faced significant stock volatility, with notable declines over various timeframes, including a 32.08% drop over the past year. Despite these challenges, the company reported a 17.91% increase in net sales and maintains strong institutional holdings at 100%.
Twist Bioscience Opens Weak with 10.57% Gap Down Amid Market Concerns
Twist Bioscience Corp. experienced a notable decline in its stock performance, contrasting with the broader market's stability. Over the past month, the company has faced a significant drop, with mixed technical indicators suggesting varying trends. Its market capitalization is around USD 1,584 million, and it does not offer dividends.
Twist Bioscience Stock Hits Day Low of $23.50 Amid Price Pressure
Twist Bioscience Corp. faced a notable stock decline today, reflecting ongoing market challenges. Despite a significant drop in stock performance over various timeframes, the company reported a 17.91% increase in net sales as of June 25 and maintains full institutional ownership. Key financial metrics indicate a negative return on equity.
Twist Bioscience Corp. Hits New 52-Week Low at $23.50
Twist Bioscience Corp. has hit a new 52-week low, reflecting a difficult year with a significant stock price decline. The company, categorized as small-cap with a market capitalization of USD 1,584 million, is currently loss-making and exhibits negative financial metrics, highlighting challenges in the biotechnology sector.
Twist Bioscience Stock Soars 7.16%, Hits Intraday High of $34.18
Twist Bioscience Corp. has seen a notable increase in stock performance, with significant gains over the past week and month. The company reported strong net sales growth and maintains high institutional holdings. However, it faces challenges with declines over the past year and year-to-date.
Twist Bioscience Corp. Experiences Revision in Stock Evaluation Amid Market Fluctuations
Twist Bioscience Corp. has experienced notable stock fluctuations, with a recent evaluation reflecting mixed technical indicators. While the stock has shown significant weekly volatility, outperforming the S&P 500, it has faced challenges over the year, resulting in a substantial decline compared to the broader market.
Is Twist Bioscience Corp. technically bullish or bearish?
As of October 3, 2025, Twist Bioscience Corp. has a mildly bearish trend overall, with mixed technical indicators, having outperformed the S&P 500 in the short term but significantly underperformed year-to-date.
Is Twist Bioscience Corp. technically bullish or bearish?
As of October 3, 2025, Twist Bioscience Corp. is in a mildly bearish trend, with mixed indicators showing short-term outperformance against the S&P 500 but significant underperformance year-to-date.
Is Twist Bioscience Corp. technically bullish or bearish?
As of October 3, 2025, Twist Bioscience Corp. shows a mixed technical outlook with a mildly bearish trend overall, despite recent outperformance against the S&P 500 in the short term, while still underperforming year-to-date.
Is Twist Bioscience Corp. technically bullish or bearish?
As of August 6, 2025, Twist Bioscience Corp. has shifted to a bearish trend, indicated by negative metrics across multiple technical indicators and a significant underperformance of -39.85% year-to-date compared to the S&P 500's 12.22%.
Is Twist Bioscience Corp. technically bullish or bearish?
As of June 18, 2025, the market trend is mildly bearish, influenced by mixed signals from indicators like the MACD, moving averages, and Bollinger Bands, despite some positive signs on the weekly timeframe.
Who are in the management team of Twist Bioscience Corp.?
As of March 2022, the management team of Twist Bioscience Corp. includes Ms. Emily Leproust as Chairman, President, and CEO, and Dr. William Banyai as Senior VP of Research and Development. The Board features independent directors, including Mr. Robert Chess as Lead Independent Director.
What does Twist Bioscience Corp. do?
Twist Bioscience Corporation is a synthetic biology company specializing in DNA synthesis, with recent net sales of $93 million and a net loss of $39 million. It has a market cap of approximately $2.03 billion and operates within the Pharmaceuticals & Biotechnology industry.
How big is Twist Bioscience Corp.?
As of Jun 18, Twist Bioscience Corp. has a market capitalization of $2.03 billion, with net sales of $347.67 million and a net profit of -$191.15 million over the last four quarters. The company reported shareholder's funds of $472.69 million and total assets of $614.32 million as of Sep 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
